Article info
PDFInflammatory bowel disease
Original article
Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
- Correspondence to Professor Xavier Hébuterne, Department of Gastroenterology and Nutrition, Archet Hospital, 151, Route Saint Antoine de Ginestière, CHU de Nice, 06202 Nice Cedex 03, France; xavier.hebuterne{at}unice.fr
Citation
Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
Publication history
- Revised February 27, 2012
- Accepted February 29, 2012
- First published April 23, 2012.
Online issue publication
October 26, 2017
Article Versions
- Previous version (30 July 2016).
- Previous version (26 October 2017).
- You are viewing the most recent version of this article.
Gut's education editor Mairi McLean discusses the paper with Xavier Hébuterne and Jean-Frédéric Colombel in the Gut podcast.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Download Supplementary Data (PDF) - Manuscript file of format pdf
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode